$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp

$ormp Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000121390023017837 Filed on March 06, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$666.0K	$681.0K	$2.703M
YoY Change	0.0%	1.04%	199.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.447M	$3.144M	$15.66M
YoY Change	-76.21%	35.28%	273.53%
% of Gross Profit
Research & Development	$4.427M	$7.277M	$27.64M
YoY Change	-24.14%	13.53%	205.84%
% of Gross Profit
Depreciation & Amortization	$37.00K	$17.00K	$58.00K
YoY Change	236.36%	41.67%	222.22%
% of Gross Profit
Operating Expenses	$4.427M	$10.42M	$27.64M
YoY Change	-62.85%	19.32%	108.91%
Operating Profit	-$5.208M		-$40.60M
YoY Change	-53.71%
Interest Expense	$1.597M	$1.004M	$3.473M
YoY Change	193.57%	-2742.11%	4791.55%
% of Operating Profit
Other Income/Expense, Net	$1.597M		$264.0K
YoY Change			112.9%
Pretax Income	-$3.611M	-$8.736M	$11.16M
YoY Change	-66.28%	7.88%	-191.1%
Income Tax		$0.00	$100.0K
% Of Pretax Income			0.9%
Net Earnings	-$3.611M	-$8.543M	-$37.76M
YoY Change	-65.36%	8.28%	223.65%
Net Earnings / Revenue	-542.19%	-1254.48%	-1397.11%
Basic Earnings Per Share	$0.08		$0.94
Diluted Earnings Per Share	$0.07	-$0.22	$0.94
COMMON SHARES
Basic Shares Outstanding	39.78M shares	39.11M shares	39.00M shares
Diluted Shares Outstanding	40.04M shares		39.00M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$24.47M	$40.82M	$155.7M
YoY Change	-82.72%	8.17%	6.45%
Cash & Equivalents	$24.10M	$40.46M	$40.46M
Short-Term Investments	$366.0K	$352.0K	$115.3M
Other Short-Term Assets	$1.423M	$1.389M	$1.389M
YoY Change	-27.1%	-22.7%	-16.17%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$155.2M	$157.1M	$157.1M
YoY Change	8.08%	6.2%	6.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$977.0K	$815.0K	$1.802M
YoY Change	-36.23%	110.05%	102.93%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$2.707M	$2.707M	$2.707M
YoY Change	-90.01%	-90.73%	-90.66%
Other Assets	$24.00K	$24.00K	$24.00K
YoY Change	0.0%	0.0%	-7.69%
Total Long-Term Assets	$4.623M	$4.533M	$4.533M
YoY Change	-83.87%	-84.83%	-84.83%
TOTAL ASSETS
Total Short-Term Assets	$155.2M	$157.1M	$157.1M
Total Long-Term Assets	$4.623M	$4.533M	$4.533M
Total Assets	$159.8M	$161.6M	$161.6M
YoY Change	-7.23%	-9.1%	-9.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.055M	$4.158M	$2.175M
YoY Change	22.51%	-12.67%	-52.04%
Accrued Expenses	$242.0K	$247.0K	$2.219M
YoY Change	2.11%	90.0%	1606.92%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.972M	$5.746M	$5.746M
YoY Change	-21.38%	-22.01%	-22.01%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$4.660M	$4.740M	$4.740M
YoY Change	26.73%	15.64%	23.37%
Total Long-Term Liabilities	$4.660M	$4.740M	$4.740M
YoY Change	26.73%	23.37%	23.37%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.972M	$5.746M	$5.746M
Total Long-Term Liabilities	$4.660M	$4.740M	$4.740M
Total Liabilities	$9.632M	$10.49M	$9.830M
YoY Change	-2.46%	-6.46%	-13.52%
SHAREHOLDERS EQUITY
Retained Earnings	-$166.5M	-$163.1M
YoY Change		28.9%
Common Stock	$481.0K	$476.0K
YoY Change		3.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$151.0M	$151.8M	$151.8M
YoY Change
Total Liabilities & Shareholders Equity	$159.8M	$161.6M	$161.6M
YoY Change	-7.23%	-9.1%	-9.1%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$3.611M	-$8.543M	-$37.76M
YoY Change	-65.36%	8.28%	223.65%
Depreciation, Depletion And Amortization	$37.00K	$17.00K	$58.00K
YoY Change	236.36%	41.67%	222.22%
Cash From Operating Activities	-$5.549M	-$8.062M	-$27.92M
YoY Change	-39.19%	16.79%	151.02%
INVESTING ACTIVITIES
Capital Expenditures	$199.0K	$308.0K	$496.0K
YoY Change	-523.4%		-5611.11%
Acquisitions
YoY Change
Other Investing Activities	-$13.00M	$11.57M	$30.71M
YoY Change	-275.59%	-111.68%	-130.94%
Cash From Investing Activities	-$13.20M	$11.26M	$30.21M
YoY Change	-279.41%	-111.37%	-130.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$10.62M
YoY Change			-82.47%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$2.430M	4.175M	$10.78M
YoY Change	6.02%	-93.11%	-82.2%
NET CHANGE
Cash From Operating Activities	-$5.549M	-8.062M	-$27.92M
Cash From Investing Activities	-$13.20M	11.26M	$30.21M
Cash From Financing Activities	$2.430M	4.175M	$10.78M
Net Change In Cash	-$16.36M	7.373M	$13.01M
YoY Change	-3210.27%	-116.24%	-126.12%
FREE CASH FLOW
Cash From Operating Activities	-$5.549M	-$8.062M	-$27.92M
Capital Expenditures	$199.0K	$308.0K	$496.0K
Free Cash Flow	-$5.748M	-$8.370M	-$28.41M
YoY Change	-36.68%	21.25%	155.68%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-35813
CY2022	dei	Entity Registrant Name EntityRegistrantName	ORAMED PHARMACEUTICALS INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0376008
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10036
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.012
CY2022	dei	Trading Symbol TradingSymbol	ORMP
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	1185 Avenue of the Americas
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Third Floor
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	169594349	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39783813	shares
CY2022	dei	Auditor Firm AuditorFirmId	1309
CY2022	dei	Auditor Name AuditorName	Kesselman & Kesselman
CY2022	dei	Auditor Location AuditorLocation	Tel Aviv, Israel
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	40464000	usd
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	27456000	usd
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	111513000	usd
CY2021Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	111077000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	3743000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7747000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	1389000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	1657000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	157109000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	147937000	usd
CY2022Q4	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	7000	usd
CY2021Q4	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	25094000	usd
CY2021Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	3875000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	2700000	usd
CY2022Q4	ormp	Amounts Funded In Respect Of Employee Rights Upon Retirement AmountsFundedInRespectOfEmployeeRightsUponRetirement	24000	usd
CY2021Q4	ormp	Amounts Funded In Respect Of Employee Rights Upon Retirement AmountsFundedInRespectOfEmployeeRightsUponRetirement	26000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	815000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	388000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	987000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	500000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	4533000	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	29883000	usd
CY2022Q4	us-gaap	Assets Assets	161642000	usd
CY2021Q4	us-gaap	Assets Assets	177820000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4158000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4535000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	1340000	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	2703000	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	1000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	247000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	130000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5746000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7368000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4000000	usd
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3340000	usd
CY2022Q4	ormp	Employee Rights Upon Retirement EmployeeRightsUponRetirement	21000	usd
CY2021Q4	ormp	Employee Rights Upon Retirement EmployeeRightsUponRetirement	22000	usd
CY2022Q4	ormp	Provision For Uncertain Tax Positionnote ProvisionForUncertainTaxPositionnote	11000	usd
CY2021Q4	ormp	Provision For Uncertain Tax Positionnote ProvisionForUncertainTaxPositionnote	11000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	647000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	370000	usd
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	61000	usd
CY2021Q4	us-gaap	Other Liabilities OtherLiabilities	99000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4740000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3842000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.012
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.012
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39563888	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39563888	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38158792	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38158792	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	476000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	459000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	314417000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	292514000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-163081000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-126520000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	151812000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	166453000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-656000	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	157000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	151156000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	166610000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	161642000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	177820000	usd
CY2022	us-gaap	Revenues Revenues	2703000	usd
	us-gaap	Revenues Revenues	904000	usd
	us-gaap	Revenues Revenues	2703000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27639000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9037000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20989000	usd
CY2022	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense	1851000	usd
	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense	898000	usd
CY2022	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	13811000	usd
	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	3295000	usd
	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	5937000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-40598000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12326000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-24223000	usd
CY2022	ormp	Financialincomes FINANCIALINCOMES	3754000	usd
	us-gaap	Profit Loss ProfitLoss	-12255000	usd
	ormp	Financialincomes FINANCIALINCOMES	158000	usd
	ormp	Financialincomes FINANCIALINCOMES	1242000	usd
CY2022	ormp	Financialexpenses FINANCIALEXPENSES	820000	usd
	ormp	Financialexpenses FINANCIALEXPENSES	87000	usd
	ormp	Financialexpenses FINANCIALEXPENSES	8000	usd
CY2022	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-37664000	usd
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-12255000	usd
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-22989000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-37764000	usd
	us-gaap	Profit Loss ProfitLoss	-22989000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-36561000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11668000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22238000	usd
CY2022	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	-1203000	usd
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	-587000	usd
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	-751000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-37764000	usd
	us-gaap	Profit Loss ProfitLoss	-12255000	usd
	us-gaap	Profit Loss ProfitLoss	-22989000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.94
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.31
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.78
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38997649	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37113137	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28469068	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	166610000	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	22000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11500000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	62000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	11119000	usd
CY2022	us-gaap	Stock Granted During Period Value Sharebased Compensation Forfeited StockGrantedDuringPeriodValueSharebasedCompensationForfeited	390000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-783000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-37764000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	151156000	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	116517000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	59933000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	639000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1776000	usd
	us-gaap	Profit Loss ProfitLoss	-12255000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	166610000	usd
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	32879000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	79983000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	21409000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	2695000	usd
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	2540000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-22989000	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	116517000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-37764000	usd
	us-gaap	Profit Loss ProfitLoss	-12255000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-22989000	usd
CY2022	us-gaap	Depreciation Depreciation	58000	usd
	us-gaap	Depreciation Depreciation	18000	usd
CY2021	us-gaap	Depreciation Depreciation	77000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	13000	usd
CY2021	ormp	Noncash Expense For Acquired Inprocess Research And Development NoncashExpenseForAcquiredInprocessResearchAndDevelopment	1040000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1550000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	34000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-187000	usd
CY2022	ormp	Changes At Fair Value Of Investments ChangesAtFairValueOfInvestments	-763000	usd
	ormp	Changes At Fair Value Of Investments ChangesAtFairValueOfInvestments	-72000	usd
CY2021	ormp	Changes At Fair Value Of Investments ChangesAtFairValueOfInvestments	876000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	11509000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1776000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2695000	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	22000	usd
CY2022	ormp	Increase Decrease In Liability For Employee Rights Upon Retirement IncreaseDecreaseInLiabilityForEmployeeRightsUponRetirement	268000	usd
	ormp	Increase Decrease In Liability For Employee Rights Upon Retirement IncreaseDecreaseInLiabilityForEmployeeRightsUponRetirement	-460000	usd
CY2021	ormp	Increase Decrease In Liability For Employee Rights Upon Retirement IncreaseDecreaseInLiabilityForEmployeeRightsUponRetirement	-586000	usd
CY2022	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	376000	usd
	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-689000	usd
CY2021	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-2060000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	93000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-703000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-904000	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2703000	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1000	usd
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	3000	usd
CY2022	us-gaap	Increase Decrease In Operating Liabilities IncreaseDecreaseInOperatingLiabilities	-38000	usd
	us-gaap	Increase Decrease In Operating Liabilities IncreaseDecreaseInOperatingLiabilities	-25000	usd
CY2021	us-gaap	Increase Decrease In Operating Liabilities IncreaseDecreaseInOperatingLiabilities	-89000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27918000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11122000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21181000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	496000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	375000	usd
CY2022	us-gaap	Proceeds From Sale Of Other Productive Assets ProceedsFromSaleOfOtherProductiveAssets	24000	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	151700000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	100000000	usd
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	18460000	usd
CY2022	ormp	Purchase Of Longterm Deposit PurchaseOfLongtermDeposit	5000	usd
CY2021	ormp	Purchase Of Longterm Deposit PurchaseOfLongtermDeposit	25000000	usd
CY2021	ormp	Payments To Acquire Mutual Funds PaymentsToAcquireMutualFunds	-3765000	usd
CY2021	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	10362000	usd
CY2022	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	178200000	usd
CY2021	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	18460000	usd
CY2022	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	6886000	usd
	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	761000	usd
CY2021	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	8209000	usd
CY2022	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	2700000	usd
CY2022	ormp	Payments To Acquire Funds In Respect Of Employee Rights Upon Retirement PaymentsToAcquireFundsInRespectOfEmployeeRightsUponRetirement	-2000	usd
CY2021	ormp	Payments To Acquire Funds In Respect Of Employee Rights Upon Retirement PaymentsToAcquireFundsInRespectOfEmployeeRightsUponRetirement	1000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	30211000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-99248000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-23764000	usd
CY2022	ormp	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	11500000	usd
	ormp	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	59933000	usd
CY2021	ormp	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	79983000	usd
CY2022	ormp	Proceeds From Stock Options And Warrants Exercised ProceedsFromStockOptionsAndWarrantsExercised	62000	usd
	ormp	Proceeds From Stock Options And Warrants Exercised ProceedsFromStockOptionsAndWarrantsExercised	639000	usd
CY2021	ormp	Proceeds From Stock Options And Warrants Exercised ProceedsFromStockOptionsAndWarrantsExercised	21409000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	783000	usd
CY2021	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	1500000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10779000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	60572000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	102892000	usd
CY2022	ormp	Effectofexchangeratechangesoncash EFFECTOFEXCHANGERATECHANGESONCASH	-64000	usd
	ormp	Effectofexchangeratechangesoncash EFFECTOFEXCHANGERATECHANGESONCASH	9000	usd
CY2021	ormp	Effectofexchangeratechangesoncash EFFECTOFEXCHANGERATECHANGESONCASH	2000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	13008000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-49789000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	57949000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27456000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	77245000	usd
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19296000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40464000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27456000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	77245000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	100000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1844000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	128000	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	563000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	730000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	582000	usd
CY2021	ormp	Inprocess Research And Developments InprocessResearchAndDevelopments	1040000	usd
CY2021	ormp	Note Receivable From Akers NoteReceivableFromAkers	1500000	usd
CY2021Q3	ormp	Additional Paid In Capital Amount AdditionalPaidInCapitalAmount	-1045000	usd
CY2021	ormp	Noncontrolling Interests NoncontrollingInterests	-1495000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of estimates in the preparation of financial statements</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statements date and the reported expenses during the reporting periods. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to stock-based compensation, expectation of milestone payments and to the expected product submission date for revenue recognition purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </p>
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	437000	usd
CY2021Q4	us-gaap	Marketable Securities MarketableSecurities	1200000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify"> </td> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>j.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentration of credit risks</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents, short and long-term deposits, which are deposited in major financial institutions, and marketable securities. The Company is of the opinion that the credit risk in respect of these balances is remote.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p>
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Other EffectiveIncomeTaxRateReconciliationTaxSettlementsOther	0.50	pure
CY2022	us-gaap	Revenue Recognition Allowances RevenueRecognitionAllowances	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>l.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue recognition</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><i>HTIT</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On November 30, 2015, the Company entered into a Technology License Agreement (the “TLA”), with Hefei Tianhui Incubator of Technologies Co. Ltd. (“HTIT”) and on December 21, 2015, the parties entered into an Amended and Restated Technology License Agreement that was further amended by the parties on June 3, 2016 and July 24, 2016 (the “HTIT License Agreement”). The HTIT License Agreement and a Stock Purchase Agreement, dated November 30, 2015, between the Company and HTIT (the “SPA”) were considered a single arrangement with multiple deliverables. The Company allocated the total consideration of $49,500 between the License Agreement and the SPA according to their fair value, as follows: $10,617 was allocated to the issuance of common stock (less issuance expenses of $23), based on the quoted price of the Company’s shares on the closing date of the SPA on December 28, 2015, and $38,883 was allocated to the License Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Under ASC 606, the Company identified a single performance obligation in the agreement and determined that the license and services are not distinct as the license and services are highly dependent on each other. In other words, HTIT cannot benefit from the license without the related services, and vice versa.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Since the customer benefits from the services as the entity performs, revenue is recognized over time through the expected product submission date in June 2023, using the input method. The Company used the input method to measure the process for the purpose of recognizing revenue, which approximates the straight-line attribution. The Company used significant judgment when it determined the product submission date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Under ASC 606, the consideration that the Company would be entitled to upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. When assessing the portion, if any, of such milestones-related consideration to be included in the transaction price, the Company first assesses the most likely outcome for each milestone and excludes the consideration related to milestones of which the occurrence is not considered the most likely outcome.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company then evaluates if any of the variable consideration determined in the first step is constrained by including in the transaction price variable consideration to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company used significant judgment when it determined the first step of variable consideration.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The potential future royalty consideration is also considered a form of variable consideration under ASC 606 as it is based on a percentage of potential future sales of the Company’s products. However, the Company applies the sales-based royalty exception and accordingly will recognize the sales-based royalty amounts when the related sale has occurred. To date, the Company has not recognized any royalty-related revenue.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As of December 31, 2022, an aggregate amount of $22,382 was allocated to the HTIT License Agreement, all of which were received through the balance sheet date. Through December 31, 2022, the Company recognized revenue associated with this agreement in the aggregate amount of $19,042 (of which $2,703 was recognized in the year ended December 31, 2022), and deferred the remaining amount of $3,340, which is presented as a contract liability on the consolidated balance sheet.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><i>Medicox</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On November 13, 2022, the Company entered into a distribution license agreement (“Medicox License Agreement”) with Medicox Co., Ltd. (“Medicox”). The Medicox License Agreement grants Medicox an exclusive license to apply for regulatory approval and distribute ORMD-0801 in the Republic of Korea. For further details, see note 6f.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Under ASC 606, the Company identified Medicox as a customer and the Medicox License Agreement as a contract with a customer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company identified a performance obligation in the Medicox License Agreement to stand-ready and provide Medicox with support in its commercialization efforts in the Republic of Korea. This performance obligation includes a non-distinct distribution license for ORMD-0801, which the Company views a predominant item in the combined performance obligation. The Company concluded that the license is not distinct, as no party other than the Company is capable of providing related services to Medicox, and both the license and related services are necessary for the customer to obtain a regulatory approval in the Republic of Korea. In addition, the agreement covers the terms of future manufacturing services, that are contingent on the completion and success of the commercialization efforts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Medicox License Agreement contains a fixed consideration of $2,000, which was received by the Company as of December 31, 2022 and is presented under long-term deferred revenues. It also contains variable consideration of contractual milestone payments and sales-based royalties.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company’s obligation to stand-ready and support Medicox will be recognized on a straight-line basis over the period the Company expects to provide support to Medicox. As of December 31, 2022, this support has not commenced, and no revenue was recognized from the Medicox License Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">If Medicox proceeds with the regulatory approval process in the Republic of Korea, the Company expects most of the revenue to be recognized in 2024, going forward. The Company notes that its Phase 3 trial did not meet its primary and secondary endpoints (see note 13). If Medicox chooses to terminate the agreement as a result of the outcome of the Phase 3 trials, the Company will accelerate revenue recognition and recognize it in 2023. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p>
CY2022	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	19042000	usd
CY2022	ormp	Deferred Revenue Recognized DeferredRevenueRecognized	2703000	usd
CY2022	ormp	Deferred Revenue Recognized Remaining Amount DeferredRevenueRecognizedRemainingAmount	3340000	usd
CY2022Q3	ormp	Nonrefundable Payment NonrefundablePayment	2000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	3356203	shares
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	3894588	shares
CY2021	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	5042299	shares
CY2021Q3	us-gaap	Lessor Operating Lease Term Of Contract LessorOperatingLeaseTermOfContract	P5Y
CY2022Q4	us-gaap	Deposit Assets DepositAssets	111513000	usd
CY2021Q4	us-gaap	Deposit Assets DepositAssets	111077000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	352000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	863000	usd
CY2022Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	85000	usd
CY2021Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	337000	usd
CY2022Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	3306000	usd
CY2021Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	6547000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	3743000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7747000	usd
CY2021Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	3875000	usd
CY2022Q4	us-gaap	Debt Securities Noncurrent DebtSecuritiesNoncurrent	3743000	usd
CY2021Q4	us-gaap	Debt Securities Noncurrent DebtSecuritiesNoncurrent	11622000	usd
CY2022Q4	us-gaap	Other Investments And Securities At Cost OtherInvestmentsAndSecuritiesAtCost	595000	usd
CY2021Q4	us-gaap	Other Investments And Securities At Cost OtherInvestmentsAndSecuritiesAtCost	595000	usd
CY2022Q4	us-gaap	Other Investments OtherInvestments	1000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	3306000	usd
CY2022	ormp	Gross Unrealized Gainslosses GrossUnrealizedGainslosses	-82000	usd
CY2022Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	3224000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	10422000	usd
CY2021	ormp	Gross Unrealized Gainslosses GrossUnrealizedGainslosses	-144000	usd
CY2021Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	10278000	usd
CY2022	us-gaap	Debt Instrument Term DebtInstrumentTerm	P1Y
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	25000	usd
CY2022Q4	us-gaap	Derivative Fixed Interest Rate DerivativeFixedInterestRate	0.0093	pure
CY2022Q4	us-gaap	Long Term Debt Maturity Date LongTermDebtMaturityDate	2023-08-10
CY2022Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	2175000	usd
CY2021Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	1692000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	529000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	1197000	usd
CY2022Q4	ormp	Accounts Payable To Institutions AccountsPayableToInstitutions	11000	usd
CY2021Q4	ormp	Accounts Payable To Institutions AccountsPayableToInstitutions	531000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	1443000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	1115000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	4158000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	4535000	usd
CY2022	us-gaap	Broadcasters License Agreement Commitments Description BroadcastersLicenseAgreementCommitmentsDescription	Pursuant to the HTIT License Agreement, HTIT will conduct, at its own expense, certain pre-commercialization and regulatory activities with respect to the Subsidiary’s technology and ORMD-0801 capsule, and will pay to the Subsidiary (i) royalties of 10% on net sales of the related commercialized products to be sold by HTIT in the Territory (“Royalties”), and (ii) an aggregate of $37,500, of which $3,000 was payable immediately, $8,000 will be paid subject to the Company entering into certain agreements with certain third parties, and $26,500 will be paid upon achievement of certain milestones and conditions. In the event that the Company does not meet certain conditions, the Royalties rate may be reduced to a minimum of 8%. Following the final expiration of the Company’s patents covering the technology in the Territory in 2033, the Royalties rate may be reduced, under certain circumstances, to 5%.
CY2022Q4	ormp	Aggregate Amount AggregateAmount	20500000	usd
CY2016Q1	ormp	Initial Payment InitialPayment	3000000	usd
CY2022	ormp	Payment Obligation Disputed PaymentObligationDisputed	6000000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2000000	usd
CY2015Q4	ormp	Stock Purchase Agreement With Htit StockPurchaseAgreementWithHTIT	In addition, on November 30, 2015, the Company entered into the SPA with HTIT, according to which, the Company issued 1,155,367 shares of common stock to HTIT for $12,000. The transaction closed on December 28, 2015.
CY2022	ormp	Total Consideration TotalConsideration	49500000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10617000	usd
CY2022	ormp	Issuance Expense IssuanceExpense	23000	usd
CY2015Q4	ormp	License Agreement LicenseAgreement	38883000	usd
CY2015Q3	ormp	Non Refundable Amount NonRefundableAmount	500000	usd
CY2022Q4	ormp	Right Terminate Years RightTerminateYears	P10Y
CY2020Q3	us-gaap	Advances For Gas Exploration Development And Production Amount AdvancesForGasExplorationDevelopmentAndProductionAmount	15000000	usd
CY2020Q3	ormp	Development Received Amount DevelopmentReceivedAmount	2000000	usd
CY2020Q3	ormp	Royalty Percentage RoyaltyPercentage	0.15	pure
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2208000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	133000	usd
CY2022Q4	ormp	Annual Lease Payment AnnualLeasePayment	-124000	usd
CY2021Q4	ormp	Annual Lease Payment AnnualLeasePayment	-124000	ils
CY2022	us-gaap	Other Expenses OtherExpenses	264000	usd
CY2021	us-gaap	Other Expenses OtherExpenses	61000	usd
CY2021	us-gaap	Other Expenses OtherExpenses	124000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	987000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	500000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	247000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	130000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	647000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	370000	usd
CY2022Q4	ormp	Total Operating Lease Liabilities TotalOperatingLeaseLiabilities	894000	usd
CY2021Q4	ormp	Total Operating Lease Liabilities TotalOperatingLeaseLiabilities	500000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y4M28D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y6M29D
CY2022	ormp	Operating Leases Percentage OperatingLeasesPercentage	0.0315	pure
CY2021	ormp	Operating Leases Percentage OperatingLeasesPercentage	0.03	pure
CY2022Q4	ormp	Operating Leases Future Minimum Payments Due Current01 OperatingLeasesFutureMinimumPaymentsDueCurrent01	291000	usd
CY2022Q4	ormp	Operating Leases Future Minimum Payments Due In Two Years1 OperatingLeasesFutureMinimumPaymentsDueInTwoYears1	291000	usd
CY2022Q4	ormp	Operating Leases Future Minimum Payments Due In Three Years1 OperatingLeasesFutureMinimumPaymentsDueInThreeYears1	228000	usd
CY2022Q4	ormp	Operating Leases Future Minimum Payments Due In Four Years1 OperatingLeasesFutureMinimumPaymentsDueInFourYears1	124000	usd
CY2022Q4	ormp	Operating Leases Future Minimum Payments Due In Five Years1 OperatingLeasesFutureMinimumPaymentsDueInFiveYears1	10000	usd
CY2022Q4	ormp	Lessee Operating Lease Liability Payments Due1 LesseeOperatingLeaseLiabilityPaymentsDue1	944000	usd
CY2022Q4	ormp	Lessee Operating Lease Liability Payments Due2 LesseeOperatingLeaseLiabilityPaymentsDue2	50000	usd
CY2022Q4	ormp	Present Value Of Leases Liabilitie PresentValueOfLeasesLiabilitie	894000	usd
CY2022Q2	us-gaap	Legal Fees LegalFees	850000	usd
CY2022Q3	ormp	Issued And Outstanding Percentage IssuedAndOutstandingPercentage	0.05	pure
CY2019Q3	us-gaap	Stock Issued During Period Shares Stock Splits StockIssuedDuringPeriodSharesStockSplits	1000000	shares
CY2019Q3	us-gaap	Shares Held In Employee Stock Option Plan Suspense Shares SharesHeldInEmployeeStockOptionPlanSuspenseShares	563646	shares
CY2022	us-gaap	Stock Issued During Period Shares Reverse Stock Splits StockIssuedDuringPeriodSharesReverseStockSplits	1823287	shares
CY2022Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	273997	shares
CY2022	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	5129000	usd
CY2021Q3	ormp	Sharebased Compensations Arrangement By Sharebased Payment Award Plan Modification Description And Terms SharebasedCompensationsArrangementBySharebasedPaymentAwardPlanModificationDescriptionAndTerms	the Company entered into a controlled equity offering agreement (the “Cantor Equity Distribution Agreement”) with Cantor Fitzgerald & Co., as agent, pursuant to which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $100,000, through a sales agent, subject to certain terms and conditions. Any shares sold will be sold pursuant to the Company’s effective shelf registration statement on Form S-3 including a prospectus dated July 26, 2021 and prospectus supplement dated September 1, 2021. The Company paid the sales agent a cash commission of 3.0% of the gross proceeds of the sale of any shares sold through the sales agent under the Cantor Equity Distribution Agreement. As of December 31, 2022 and through March 6, 2023, 1,778,147 and 1,971,447 shares were issued under the Cantor Equity Distribution Agreement for aggregate net proceeds of $23,823 and $26,253, respectively. g. On November 3, 2021, the Company entered into a securities purchase agreement with several institutional and accredited investors (the “Purchasers”), pursuant to which the Company agreed to sell, in a registered direct offering (the “Offering”), an aggregate of 2,000,000 shares of the Company’s common stock to the Purchasers for an offering price of $25 per share. The closing of the sale of the shares occurred on November 5, 2021. The net proceeds to the Company from the Offering, after deducting the placement agent’s fees and expenses and the Company’s Offering expenses, were approximately $46,375.
CY2022	ormp	Issuance Of Common Stock IssuanceOfCommonStock	150705	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	158375	shares
CY2021Q4	ormp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice	4.78
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	232175	shares
CY2021Q3	ormp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice	5.57
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	3407820	shares
CY2020Q3	ormp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice	6.98
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	4200	shares
CY2022	ormp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice	4.8
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	73800	shares
	ormp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice	7.25
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	3175645	shares
CY2021	ormp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice	7.07
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	3470	shares
CY2022	ormp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice	7.81
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	150705	shares
CY2022Q4	ormp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice	4.71
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	158375	shares
CY2021Q4	ormp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice	4.78
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	232175	shares
CY2021Q3	ormp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice	5.57
CY2022Q4	ormp	Sharebased Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number SharebasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	150705	shares
CY2022Q4	ormp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice	4.71
CY2021Q4	ormp	Sharebased Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number SharebasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	158375	shares
CY2021Q4	ormp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice	4.78
CY2021Q3	ormp	Sharebased Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number SharebasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	232175	shares
CY2021Q3	ormp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageExercisePrice	5.57
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.4
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	150000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1987000	usd
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	10.4
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.6107	pure
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0064	pure
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y2M15D
CY2021Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	680000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	15000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.33
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	11.33
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.6439	pure
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0076	pure
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y11M8D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	100000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	15.1
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	The options shall vest as follows: 12,500 on December 31, 2021, three equal annual installments of 25,000 on each of December 31, 2022, 2023 and 2024 and 12,500 on August 4, 2025.
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	37500	shares
CY2022	ormp	Expired Terms ExpiredTerms	2031-08-04
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	860000	usd
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	15.1
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.6198	pure
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0082	pure
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y2M1D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	20.19
CY2021Q3	ormp	Installment Description InstallmentDescription	The options shall vest in four equal installments of 12,500 options on each of June 27, 2022, June 27, 2023, June 27, 2024 and June 27, 2025
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	25000	usd
CY2022Q4	ormp	Shares Held In Employee Stock Option Plan Suspense Shares1 SharesHeldInEmployeeStockOptionPlanSuspenseShares1	1572	shares
CY2022Q1	ormp	Aggregate Shares AggregateShares	150000	shares
CY2022Q1	us-gaap	Shortterm Debt Fair Value ShorttermDebtFairValue	2084000	usd
CY2022Q1	ormp	Stock Based Compensation Description StockBasedCompensationDescription	the Company granted an aggregate of 207,500 RSUs representing a right to receive shares of the Company’s common stock to the Company’s employees and members of the Board of Directors as follows: 63,000 to the President and Chief Executive Officer; 42,000 to the Chief Scientific Officer; 21,000 to the Chief Operating and Business Officer, 19,000 to the Chief Financial Officer and Treasurer, 19,000 to the Chief Commercial Officer, 18,000 to the Chief Legal Officer and Secretary (effective as of the time his employment with the Company commenced on January 9, 2022), an aggregate of 24,000 to four board members and 1,500 to an employee. The RSUs vest in four equal annual installments on each of January 1, 2023, 2024, 2025 and 2026. The total fair value of these RSUs on the date of grant was $2,849, using the quoted closing market share price of $13.89 on the Nasdaq Capital Market on the date of grant and $12.03 for the Chief Legal Officer’s grant (equivalent to the closing price of the Company’s common stock on January 10, 2022, which represents the first trading date after his employment with the Company commenced).
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	30000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	12.03
CY2022Q1	ormp	Expired Terms ExpiredTerms	2032-01-03
CY2022Q2	ormp	Stock Based Compensation Description StockBasedCompensationDescription	the Company granted 4,500 RSUs representing a right to receive shares of the Company’s common stock to Mr. Yadin Rozov, a member of the Company’s board of directors. The RSUs shall vest in four equal annual installments on each of May 2, 2023, 2024, 2025 and 2026. The total fair value of these RSUs on the date of grant was $23, using the quoted closing market share price of $5.14 on the Nasdaq Capital Market on the last trading day before the date of grant.
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	7500	shares
CY2022Q2	ormp	Expired Terms ExpiredTerms	2032-05-02
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	34000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	8.47
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	The options will vest in four annual installments as follows: the first installment vested immediately on the grant date and the remaining three installments shall vest on each of December 31, 2022, 2023 and 2024.
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	665000	usd
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.79
	ormp	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumption Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1	P6Y1M28D
	ormp	Expected Stock Price Volatility ExpectedStockPriceVolatility	0.6162	pure
	ormp	Risk Free Interest Rate RiskFreeInterestRate	0.0093	pure
CY2022	ormp	Expected Dividend Yield ExpectedDividendYield	0	pure
	ormp	Expected Dividend Yield ExpectedDividendYield	0	pure
CY2021	ormp	Expected Dividend Yield ExpectedDividendYield	0	pure
CY2021Q4	ormp	Number Of Options Options Outstanding NumberOfOptionsOptionsOutstanding	1942117	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.14
CY2021Q3	ormp	Number Of Options Options Outstanding NumberOfOptionsOptionsOutstanding	1905783	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.79
CY2020Q3	ormp	Number Of Options Options Outstanding NumberOfOptionsOptionsOutstanding	1597149	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.47
CY2022	ormp	Share Based Compensation Arrangement By Number Of Options Granted ShareBasedCompensationArrangementByNumberOfOptionsGranted	359000	shares
CY2022	ormp	Share Based Compensation Arrangement By Weighted Average Exercise Price Granted ShareBasedCompensationArrangementByWeightedAverageExercisePriceGranted	13.55
	ormp	Share Based Compensation Arrangement By Number Of Options Granted ShareBasedCompensationArrangementByNumberOfOptionsGranted	50000	shares
	ormp	Share Based Compensation Arrangement By Weighted Average Exercise Price Granted ShareBasedCompensationArrangementByWeightedAverageExercisePriceGranted	20.19
CY2021	ormp	Share Based Compensation Arrangement By Number Of Options Granted ShareBasedCompensationArrangementByNumberOfOptionsGranted	455000	shares
CY2021	ormp	Share Based Compensation Arrangement By Weighted Average Exercise Price Granted ShareBasedCompensationArrangementByWeightedAverageExercisePriceGranted	11.46
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	48334	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	10.59
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	52584	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.78
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	144000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	4.08
CY2022	ormp	Stock Issued During Period Shares Stock Options Exercised1 StockIssuedDuringPeriodSharesStockOptionsExercised1	67107	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.03
	ormp	Stock Issued During Period Shares Stock Options Exercised1 StockIssuedDuringPeriodSharesStockOptionsExercised1	13666	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.32
CY2021	ormp	Stock Issued During Period Shares Stock Options Exercised1 StockIssuedDuringPeriodSharesStockOptionsExercised1	93782	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.42
CY2022Q4	ormp	Number Of Options Options Outstanding NumberOfOptionsOptionsOutstanding	2041676	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.47
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1261426	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice	6.86
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	852031	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice	6.22
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	859447	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.99
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.47
CY2021Q4	ormp	Number Of Options Options Outstanding NumberOfOptionsOptionsOutstanding	1942117	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.14
CY2021Q3	ormp	Number Of Options Options Outstanding NumberOfOptionsOptionsOutstanding	1905783	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.47
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	2041676	shares
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P6Y11M8D
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	8.47
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1261426	shares
CY2021	ormp	Share Based Payment Arrangement Noncash Expense ShareBasedPaymentArrangementNoncashExpense	22000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4500000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4500000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	10000	shares
CY2022	ormp	Sharebased Payment Arrangement Noncash Expenses SharebasedPaymentArrangementNoncashExpenses	5262000	usd
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	3473000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	114000	usd
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	130000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	176000	usd
CY2022	us-gaap	Other Income OtherIncome	100000	usd
	us-gaap	Other Income OtherIncome	43000	usd
CY2021	us-gaap	Other Income OtherIncome	217000	usd
CY2021	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	6000	usd
CY2021	ormp	Financial Income FinancialIncome	889000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	3754000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	158000	usd
CY2021Q3	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	1242000	usd
	us-gaap	Foreign Currency Transaction Loss Before Tax ForeignCurrencyTransactionLossBeforeTax	11000	usd
CY2021	us-gaap	Foreign Currency Transaction Loss Before Tax ForeignCurrencyTransactionLossBeforeTax	2000	usd
CY2022	us-gaap	Noninterest Expense Commission Expense NoninterestExpenseCommissionExpense	14000	usd
	us-gaap	Noninterest Expense Commission Expense NoninterestExpenseCommissionExpense	2000	usd
CY2021	us-gaap	Noninterest Expense Commission Expense NoninterestExpenseCommissionExpense	5000	usd
CY2022	us-gaap	Debt Securities Gain Loss DebtSecuritiesGainLoss	43000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	763000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	72000	usd
	us-gaap	Other Noninterest Expense OtherNoninterestExpense	2000	usd
CY2021	us-gaap	Other Noninterest Expense OtherNoninterestExpense	1000	usd
CY2022	ormp	Financial Expenses FinancialExpenses	820000	usd
	ormp	Financial Expenses FinancialExpenses	87000	usd
CY2021	ormp	Financial Expenses FinancialExpenses	8000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	27610000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	22230000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5195000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4429000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	32805000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	26659000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	11164000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	3639000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	5307000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	26500000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	8616000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	17682000	usd
CY2022	ormp	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest1 IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest1	37664000	usd
	ormp	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest1 IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest1	12255000	usd
CY2021	ormp	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest1 IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest1	22989000	usd
CY2022	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	100000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	100000	usd
CY2022	ormp	Loss Before Income Taxes As Reported In The Consolidated Statement Of Comprehensive Loss LossBeforeIncomeTaxesAsReportedInTheConsolidatedStatementOfComprehensiveLoss	-37664000	usd
	ormp	Loss Before Income Taxes As Reported In The Consolidated Statement Of Comprehensive Loss LossBeforeIncomeTaxesAsReportedInTheConsolidatedStatementOfComprehensiveLoss	-12255000	usd
CY2021	ormp	Loss Before Income Taxes As Reported In The Consolidated Statement Of Comprehensive Loss LossBeforeIncomeTaxesAsReportedInTheConsolidatedStatementOfComprehensiveLoss	-22989000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	7909000	usd
	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	2574000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	4828000	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	354000	usd
CY2022	us-gaap	Income Tax Reconciliation Deductions IncomeTaxReconciliationDeductions	100000	usd
	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2497000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4872000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1152000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7290000	usd
	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	249000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	310000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	533000	usd
	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	172000	usd
CY2022	us-gaap	Other Noninterest Expense OtherNoninterestExpense		usd
CY2022	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	100000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11000	usd
CY2021Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11000	usd
CY2020Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11000	usd
CY2021Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11000	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	26659000	usd
CY2022	ormp	Operating Loss Carryforwards Valuation Allowance Additions OperatingLossCarryforwardsValuationAllowanceAdditions	6146000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	32805000	usd
CY2021Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	25073000	usd
	ormp	Operating Loss Carryforwards Valuation Allowance Additions OperatingLossCarryforwardsValuationAllowanceAdditions	1585000	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	26659000	usd
CY2020Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	19392000	usd
CY2021	ormp	Operating Loss Carryforwards Valuation Allowance Additions OperatingLossCarryforwardsValuationAllowanceAdditions	5681000	usd
CY2021Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	25073000	usd
CY2022Q4	us-gaap	Sponsor Fees SponsorFees	88023	ils
CY2022Q4	us-gaap	Sponsor Fees SponsorFees	25000	usd
CY2022Q4	us-gaap	Salaries And Wages SalariesAndWages	46901	ils
CY2022Q4	us-gaap	Salaries And Wages SalariesAndWages	13000	usd
CY2021Q1	ormp	Asset Acquisitions Description AssetAcquisitionsDescription	On that date, Oravax’s assets were (1) in process research and development of COVID-19 vaccine technology; and (2) $1,500 to be received in cash. According to the Stockholders Agreement, Oravax issued 1,890,000 shares of its capital stock to the Company, representing 63% of the issued and outstanding share capital of Oravax, on a fully diluted basis, as of the date of issuance, for which the Company paid $1,500.
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.15	pure
CY2022	us-gaap	Other General Expense OtherGeneralExpense	1040000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	ormp	Royalty Net Sales RoyaltyNetSales	0.025	pure
CY2022Q4	us-gaap	Other Minority Interests OtherMinorityInterests	1495000	usd
CY2022	dei	City Area Code CityAreaCode	844
CY2022	dei	Local Phone Number LocalPhoneNumber	967-2633
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.31
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.78
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.94
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37113137	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38997649	shares
CY2022	ormp	Noncash Expense For Acquired Inprocess Research And Development NoncashExpenseForAcquiredInprocessResearchAndDevelopment		usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet		usd
CY2022	ormp	Payments To Acquire Mutual Funds PaymentsToAcquireMutualFunds		usd
CY2022	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities		usd
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments		usd
	ormp	Payments To Acquire Funds In Respect Of Employee Rights Upon Retirement PaymentsToAcquireFundsInRespectOfEmployeeRightsUponRetirement		usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2022	ormp	Inprocess Research And Developments InprocessResearchAndDevelopments		usd
CY2022	ormp	Note Receivable From Akers NoteReceivableFromAkers		usd
CY2022Q4	ormp	Additional Paid In Capital Amount AdditionalPaidInCapitalAmount		usd
CY2022	ormp	Noncontrolling Interests NoncontrollingInterests		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2022	ormp	Share Based Compensation Arrangementby Share Based Payment Award Equity Instruments Other Than Options Granted In Period Weighted Average Exercise Price ShareBasedCompensationArrangementbyShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	ormp	Share Based Compensation Arrangementby Share Based Payment Award Equity Instruments Other Than Options Granted In Period Weighted Average Exercise Price ShareBasedCompensationArrangementbyShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
	ormp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax		usd
CY2021	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax		usd
CY2022	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss		usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss		usd
CY2022	ormp	Financial Income FinancialIncome		usd
	ormp	Financial Income FinancialIncome		usd
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent		usd
CY2022	us-gaap	Foreign Currency Transaction Loss Before Tax ForeignCurrencyTransactionLossBeforeTax		usd
CY2021	us-gaap	Debt Securities Gain Loss DebtSecuritiesGainLoss		usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax		usd
CY2022	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations		usd
	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations		usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense		usd
CY2022	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease		usd
	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease		usd
CY2021	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001176309

Files In Submission

Name	View Source	Status
ormp-20221231_def.xml	Edgar Link	unprocessable
0001213900-23-017837-index-headers.html	Edgar Link	pending
0001213900-23-017837-index.html	Edgar Link	pending
0001213900-23-017837.txt	Edgar Link	pending
0001213900-23-017837-xbrl.zip	Edgar Link	pending
ex10-2_001.jpg	Edgar Link	pending
ex23-1_001.jpg	Edgar Link	pending
f10k2022ex10-13_oramedpharma.htm	Edgar Link	pending
f10k2022ex10-14_oramedpharma.htm	Edgar Link	pending
f10k2022ex10-1_oramedpharma.htm	Edgar Link	pending
f10k2022ex10-23_oramedpharma.htm	Edgar Link	pending
f10k2022ex10-2_oramedpharma.htm	Edgar Link	pending
f10k2022ex10-41_oramedpharma.htm	Edgar Link	pending
f10k2022ex10-42_oramedpharma.htm	Edgar Link	pending
f10k2022ex23-1_oramedpharma.htm	Edgar Link	pending
f10k2022ex31-1_oramedpharma.htm	Edgar Link	pending
f10k2022ex31-2_oramedpharma.htm	Edgar Link	pending
f10k2022ex32-1_oramedpharma.htm	Edgar Link	pending
f10k2022ex32-2_oramedpharma.htm	Edgar Link	pending
f10k2022ex4-4_oramedpharma.htm	Edgar Link	pending
f10k2022_oramedpharma.htm	Edgar Link	pending
f10k2022_oramedpharma_htm.xml	Edgar Link	completed
Financial_Report.xlsx	Edgar Link	pending
fin_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ormp-20221231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
ormp-20221231_lab.xml	Edgar Link	unprocessable
ormp-20221231_pre.xml	Edgar Link	unprocessable
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ormp-20221231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp

2023 Q1 Form 10-K Financial Statement

#000121390023017837 Filed on March 06, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORMP ORAMED PHARMACEUTICALS INC. Stock $ormp

2023 Q1 Form 10-K Financial Statement

#000121390023017837 Filed on March 06, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp